Hostname: page-component-78c5997874-lj6df Total loading time: 0 Render date: 2024-11-10T08:43:38.813Z Has data issue: false hasContentIssue false
  • English
  • Français

Quetiapine: Results of four phase II and III clinical trials

Published online by Cambridge University Press:  16 April 2020

DJ King
DJ King*
Affiliation:
Department of Therapeutics and Pharmacology, Queen's University of Belfast, Belfast, Northern Ireland
Get access

Summary

The data on efficacy and tolerance from four (phase II and III) trials of quetiapine (Seroquel® or ICI 204,636) in a total of 1,461 patients with acute exacerbations of chronic or sub-chronic schizophrenia are briefly reviewed. Together, the results of these trials have demonstrated antipsychotic efficacy in comparison with placebo and equivalent efficacy to haloperidol. In spite of its short plasma elimination half-life, quetiapine is equally effective when given in twice-daily and three-time daily doses. The optimum dose is between 300 mg and 400 mg per day, and the main and most consistent adverse effect is sedation. It has a low extrapyramidal side effect liability and does not produce sustained elevations in plasma prolactin levels.

Keywords

quetiapineschizophreniaEPSclinical data
Type
Research Article
Information
European Psychiatry , Volume 13 , Issue S1 , 1998 , pp. 15s - 21s
Copyright
Copyright © Elsevier, Pari 1998

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

American Psychiatric Associations, Diagnostic and Statistical Manual of Mental Disorders, Third edition revised, Vienna: APA, 1987Google Scholar
Farde, L, Nordström, A-L, Wiesel, FA, Pauli, S, Halldin, C, Sedvall, GPositron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical antipsychotics and clozapine Arch Gen Psychiatry 1992; 49: 538–544CrossRefGoogle ScholarPubMed
Goldstein, JM, Litwin, LC, Sutton, EB, Malick, JBSeroquel: electrophysiological profile of a potential atypical antipsychotic Psychopharmacology 1993; 112: 293–298CrossRefGoogle ScholarPubMed
Johnson, AL, Johnson, DAWPeer review of ‘Risperidone in the treatment of patients with chronic schizophrenia: a multinational, multi-centre, double-blind, parallel-group study versus haloperidol’ Br J Psychiatry 1995; 166: 727–733CrossRefGoogle Scholar
Mantel, N, Maenszel, WStatistical aspects of the analyses of data from retrospective studies of disease J Nat Cancer Institute 2241959Google Scholar
Möller, H-J, van Praag, HM, Aufdembrinke, B, Bailey, P, Barnes, TRE, Beck, J, et al.Negative symptoms in schizophrenia: considerations for clinical trials Psychopharmacology 1994; 115: 221–228CrossRefGoogle ScholarPubMed
Peuskens, JRisperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol Br J Psychiatry 1995; 166: 712–726CrossRefGoogle ScholarPubMed
Robertson, GS, Matsumura, H, Fibiger, HCInduction patterns of c-foslike immunoreactivity in the forebrain as predictors of atypical antipsychotic activity J Pharmacol Exp Ther 1994; 271: 1058–1066Google ScholarPubMed
Wong, YWJ, Ewing, BJ, Fabre, LF, Thyrum, PT, Yeh, CMultiple dose pharmacokinetics and dose proportionality study of Seroquel (ICI 204,636) in male schizophrenic patients Euro Neuropsychopharmacol 1996; 6(suppl 3): 38 Abs P-2-5CrossRefGoogle Scholar
Submit a response

Comments

No Comments have been published for this article.